1. CXCL10 is a potential biomarker and associated with immune infiltration in human papillary thyroid cancer
- Author
-
Hui-Li Fan, Xu Lin, Jingfang Wu, Gang Xue, Da Pei, Hao-Yu Wang, and Xiao-Jing Qin
- Subjects
0301 basic medicine ,Male ,tumor ,Stromal cell ,endocrine system diseases ,Bioinformatics ,Biophysics ,Cellular defense response ,Kaplan-Meier Estimate ,Biochemistry ,Papillary thyroid cancer ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,medicine ,Biomarkers, Tumor ,Tumor Microenvironment ,Humans ,Protein Interaction Maps ,Thyroid Neoplasms ,Molecular Biology ,Thyroid cancer ,Diagnostics & Biomarkers ,Research Articles ,Cancer ,Tumor microenvironment ,Innate immune system ,business.industry ,Gene Expression Profiling ,Cell Biology ,Genomics ,Middle Aged ,medicine.disease ,Acquired immune system ,Chemokine CXCL10 ,030104 developmental biology ,Thyroid Cancer, Papillary ,030220 oncology & carcinogenesis ,Cancer research ,Female ,business ,Algorithms ,Signal Transduction - Abstract
Background: In recent years, the annual incidence of thyroid cancer (TC) has increased, with papillary thyroid cancer (PTC) identified as the most commonwinwordpathological type accounting for approximately 80% of all thyroid cancer cases. The tumor microenvironment is known to play a vital role in tumor information transmission and immune detection. Methods: In the present study, we examined gene expression data from 518 patients with PTC. The ESTIMATE algorithm was used to calculate immune and stromal scores of PTC patients. Based on a protein–protein interaction (PPI) network, functional enrichment and overall survival analyses, C-X-C motif chemokine ligand 10 (CXCL10) was identified as a core gene. We further investigated the roles of core genes of PTC in the tumor immune microenvironment using LinkedOmics, GSEA, and TIMER tools. Results: Immune, stromal and ESTIMATE scores were related to clinicopathological variables of patients with PTC, but not survival outcomes. Eight differentially expressed genes (DEGs) were associated with survival outcome. In addition, immunochemical staining experiments revealed lower expression of CXCL10 in PTC than paracancerous tissues. GSEA pathway enrichment analysis revealed downregulation of CXCL10 in multiple cancer pathways. CXCL10 and related genes were enriched in pathways related to adaptive immune response, cellular defense response and regulation of innate immune response. Conclusion: The tumor microenvironment plays a critical role in development of PTC and CXCL10 may serve as a novel target of precision therapy for this patient population.
- Published
- 2021